OmniAb (OABI) Preferred Stock Liabilities (2021 - 2022)
OmniAb's (OABI) quarterly Preferred Stock Liabilities came in at $237.2 million in Q3 2022, up 0.61% year-on-year from $235.8 million in Q3 2021, and little changed on a QoQ basis from $236.1 million in Q2 2022.
OmniAb (OABI) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
OmniAb (OABI) has 2 years of Preferred Stock Liabilities data on file, last reported at $237.2 million in Q3 2022.
- On a quarterly basis, Preferred Stock Liabilities rose 0.61% year-over-year to $237.2 million in Q3 2022; TTM through Sep 2022 was $237.2 million, a 0.61% increase from a year earlier, with the FY2021 full-year figure at $235.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2022 stood at $237.2 million, roughly flat from $236.1 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for OABI reached as high as $237.2 million in Q3 2022 and fell as low as $235.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.75 Mn |
| Dec 31, 2021 | 235.75 Mn |
| Sep 30, 2021 | 235.75 Mn |